0.53
Schlusskurs vom Vortag:
$0.492
Offen:
$0.49
24-Stunden-Volumen:
6.28M
Relative Volume:
0.95
Marktkapitalisierung:
$114.11M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.7067
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
+13.98%
1M Leistung:
-13.40%
6M Leistung:
-73.63%
1J Leistung:
-10.43%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SGMO
Sangamo Therapeutics Inc
|
0.53 | 114.11M | 52.29M | -134.84M | -117.11M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-13 | Hochstufung | Truist | Hold → Buy |
2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
2022-06-13 | Fortgesetzt | Wedbush | Neutral |
2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
2021-01-06 | Eingeleitet | Stifel | Hold |
2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
2020-09-08 | Eingeleitet | BofA Securities | Buy |
2020-07-07 | Eingeleitet | SunTrust | Buy |
2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
2018-10-10 | Eingeleitet | Guggenheim | Buy |
2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2017-06-22 | Fortgesetzt | Jefferies | Buy |
2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
2015-10-23 | Fortgesetzt | Jefferies | Buy |
2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
2010-07-29 | Bestätigt | Wedbush | Outperform |
2009-10-19 | Eingeleitet | Brean Murray | Sell |
2009-10-07 | Bestätigt | Leerink Swann | Outperform |
2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com
Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World
Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | - GuruFocus
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Sangamo Therapeutics prices $23M securities offering - MSN
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus
Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace
Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria
Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus
Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | SGMO Stock News - GuruFocus
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace
Sangamo: Q1 Earnings Snapshot - San Antonio Express-News
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa
Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus
Sangamo hits milestone toward accelerated approval for ST-920 - Fabry Disease News
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - BioSpace
Sangamo Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):